Therapeutic uses of autologous endothelial cells for vascular disease

Rajiv Gulati, Amir Lerman, Robert D. Simari

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Endothelial cells play important structural and functional roles in vascular homoeostasis. Perturbations in endothelial cell number and function are directly involved with the initiation and progression of multiple cardiovascular diseases, including atherosclerosis, hypertension and congestive heart failure. Attempts to modify these disorders have included pharmacological strategies to improve vascular and thus endothelial function. A goal of biological approaches to these disorders is the delivery of endothelial cells that might act to provide beneficial endothelial-derived factors. However, this approach has generally been limited by the lack of readily available autologous endothelial cells for delivery. The isolation of circulation-derived endothelial progenitor cells allows for direct access to autologous endothelial cells for preclinical and clinical studies. Preclinical studies using autologous endothelial cells have demonstrated beneficial effects when delivered in animal models of vascular injury and grafting. These effects are related to the endothelial nature of the cells and may be paracrine in nature. Ongoing studies are aimed at defining the nature of these effects and optimizing delivery strategies cognizant of these mechanisms.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalClinical Science
Volume109
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

Therapeutic Uses
Vascular Diseases
Endothelial Cells
Blood Vessels
Vascular Grafting
Vascular System Injuries
Atherosclerosis
Homeostasis
Cardiovascular Diseases
Animal Models
Heart Failure
Cell Count
Pharmacology
Hypertension

Keywords

  • Atherosclerosis
  • Culture-modified mononuclear cell (CMMC)
  • Endothelial cell
  • Endothelium
  • Restenosis
  • Vascular disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic uses of autologous endothelial cells for vascular disease. / Gulati, Rajiv; Lerman, Amir; Simari, Robert D.

In: Clinical Science, Vol. 109, No. 1, 07.2005, p. 27-37.

Research output: Contribution to journalArticle

@article{386da939e28a4a77b944cc15d3319135,
title = "Therapeutic uses of autologous endothelial cells for vascular disease",
abstract = "Endothelial cells play important structural and functional roles in vascular homoeostasis. Perturbations in endothelial cell number and function are directly involved with the initiation and progression of multiple cardiovascular diseases, including atherosclerosis, hypertension and congestive heart failure. Attempts to modify these disorders have included pharmacological strategies to improve vascular and thus endothelial function. A goal of biological approaches to these disorders is the delivery of endothelial cells that might act to provide beneficial endothelial-derived factors. However, this approach has generally been limited by the lack of readily available autologous endothelial cells for delivery. The isolation of circulation-derived endothelial progenitor cells allows for direct access to autologous endothelial cells for preclinical and clinical studies. Preclinical studies using autologous endothelial cells have demonstrated beneficial effects when delivered in animal models of vascular injury and grafting. These effects are related to the endothelial nature of the cells and may be paracrine in nature. Ongoing studies are aimed at defining the nature of these effects and optimizing delivery strategies cognizant of these mechanisms.",
keywords = "Atherosclerosis, Culture-modified mononuclear cell (CMMC), Endothelial cell, Endothelium, Restenosis, Vascular disease",
author = "Rajiv Gulati and Amir Lerman and Simari, {Robert D.}",
year = "2005",
month = "7",
doi = "10.1042/CS20050002",
language = "English (US)",
volume = "109",
pages = "27--37",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Therapeutic uses of autologous endothelial cells for vascular disease

AU - Gulati, Rajiv

AU - Lerman, Amir

AU - Simari, Robert D.

PY - 2005/7

Y1 - 2005/7

N2 - Endothelial cells play important structural and functional roles in vascular homoeostasis. Perturbations in endothelial cell number and function are directly involved with the initiation and progression of multiple cardiovascular diseases, including atherosclerosis, hypertension and congestive heart failure. Attempts to modify these disorders have included pharmacological strategies to improve vascular and thus endothelial function. A goal of biological approaches to these disorders is the delivery of endothelial cells that might act to provide beneficial endothelial-derived factors. However, this approach has generally been limited by the lack of readily available autologous endothelial cells for delivery. The isolation of circulation-derived endothelial progenitor cells allows for direct access to autologous endothelial cells for preclinical and clinical studies. Preclinical studies using autologous endothelial cells have demonstrated beneficial effects when delivered in animal models of vascular injury and grafting. These effects are related to the endothelial nature of the cells and may be paracrine in nature. Ongoing studies are aimed at defining the nature of these effects and optimizing delivery strategies cognizant of these mechanisms.

AB - Endothelial cells play important structural and functional roles in vascular homoeostasis. Perturbations in endothelial cell number and function are directly involved with the initiation and progression of multiple cardiovascular diseases, including atherosclerosis, hypertension and congestive heart failure. Attempts to modify these disorders have included pharmacological strategies to improve vascular and thus endothelial function. A goal of biological approaches to these disorders is the delivery of endothelial cells that might act to provide beneficial endothelial-derived factors. However, this approach has generally been limited by the lack of readily available autologous endothelial cells for delivery. The isolation of circulation-derived endothelial progenitor cells allows for direct access to autologous endothelial cells for preclinical and clinical studies. Preclinical studies using autologous endothelial cells have demonstrated beneficial effects when delivered in animal models of vascular injury and grafting. These effects are related to the endothelial nature of the cells and may be paracrine in nature. Ongoing studies are aimed at defining the nature of these effects and optimizing delivery strategies cognizant of these mechanisms.

KW - Atherosclerosis

KW - Culture-modified mononuclear cell (CMMC)

KW - Endothelial cell

KW - Endothelium

KW - Restenosis

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=21744438827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744438827&partnerID=8YFLogxK

U2 - 10.1042/CS20050002

DO - 10.1042/CS20050002

M3 - Article

VL - 109

SP - 27

EP - 37

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 1

ER -